Meier et al., 2004b), GLP-1 has a circulating half-life of 12 min (Meek et al., 2021)
Other research highlights: 30% of GLP-1 users tested positive for SIBO or IMO even after accounting for diabetes (5) GLP-1 medicines caused microbiome changes and altered metabolism in mice (6) GLP-1 medicines tested in humans only had noticeable microbiome changes by 48 weeks (7) Despite not necessarily having slower gut motility, one study found that 88.9% of obese patients had SIBO (8) A meta analysis of people with IBS symptoms, found that up to 78% of people had SIBO, many of whom were undiagnosed (9) Overall, Sun and colleagues (1) could not prove a mechanistic link between GLP-1 medications and SIBO, however they did find that SIBO was twice as likely in GLP-1 users
Beyond week 12: Doses may increase to 1.7mg or 2.4mg for patients who tolerate lower doses well but need additional appetite suppression
Hydration, hydration, hydration A quick note on hydration, and dont underestimate this one
Q: Which is better for liver health NAC or glutathione
By covalent (albiglutide, dulaglutide) or no-covalent (semaglutide) coupling to larger molecules with slow clearance, analogs with even more prolonged activity have been produced so that there are now several once-weekly agonists on the market